GILD in “The Patent Cliff Sparks a Biotech Land Grab”
Gilead Sciences, Inc.
Heavy dependence on HIV cash flows and uneven returns from past oncology acquisitions create pressure to replenish growth externally without overpaying.
GILD impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to GILD’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading GILD impact map…
Price history, marked with story events
Oct 7, 2019 – Oct 5, 2020 · 252 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BEAR side — Heavy dependence on HIV cash flows and uneven returns from past oncology acquisitions create pressure to replenish growth externally without overpaying.
Read the full The Patent Cliff Sparks a Biotech Land Grab storyBull side
0 storiesNo bull-side stories for GILD yet.
Bear side
2 stories- America Imports the World's Drug Prices
GILD in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Gilead's patented HIV and oncology portfolio earns substantial US revenue and could suffer if lower foreign net prices anchor domestic reimbursement.
- Viewing
GILD in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Heavy dependence on HIV cash flows and uneven returns from past oncology acquisitions create pressure to replenish growth externally without overpaying.